[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344946-105":59,"doc-detail-344946-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cancer-cell-intrinsic-inflammasome-protein-asc-links-innate-immunity-with-mitochondrial-metabolism-in-driving-pancreatic-cancer","Cancer cell-intrinsic inflammasome protein ASC links innate immunity with mitochondrial metabolism in driving pancreatic cancer","","Pancreatic ductal adenocarcinoma is propelled by dysregulated innate immunity that sustains tumor-promoting inflammation, yet the actionable molecular regulators remain unclear. Elevated tumoral ASC and its downstream effector Caspase-1 colocalize with the pancreatic ductal epithelium and predict poor survival in patients. In KRAS-driven KPC models, ablating ASC in the pancreatic epithelium or targeting extracellular ASC suppresses tumorigenesis, with transcriptomic and multiplex imaging aligning epithelial ASC activity to mitochondrial respiration, metabolic rewiring, and immune pathways, supporting ASC as a therapeutic bridge among immunity, mitochondrial dysfunction, and metabolic reprogramming.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cancer-cell-intrinsic-inflammasome-protein-asc-links-innate-immunity-with-mitochondrial-metabolism-in-driving-pancreatic-cancer/344946/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cancer-cell-intrinsic-inflammasome-protein-asc-links-innate-immunity-with-mitochondrial-metabolism-in-driving-pancreatic-cancer/344946.png","ImageObject",300,407,{"name":92,"@type":93},"Aurora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-08","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What relationship between ASC and prognosis is reported in pancreatic cancer patients?","Question",{"text":112,"@type":113},"Tumoral ASC expression, along with Caspase-1, is primarily colocalized to the pancreatic ductal epithelium and is prognostic for poor survival.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does targeting ASC affect pancreatic tumor development in the KPC mouse model?",{"text":117,"@type":113},"Global or conditional ablation of ASC, or nanobody-mediated targeting of extracellular ASC, suppresses pancreatic tumorigenesis.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanisms link ASC-containing inflammasomes to PDAC according to the article?",{"text":121,"@type":113},"Epithelial-derived ASC aligns with pathways for mitochondrial respiration, metabolic reprogramming (including glycolysis), and immune responses, forming a molecular bridge between innate immunity, mitochondrial dysfunction, and metabolic changes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},344946,1790632483,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},4810365810221,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Article [https://doi.org/10.1038/s41467-026-69398-w](https://doi.org/10.1038/s41467-026-69398-w)  \nCancer cell-intrinsic inﬂammasome protein ASC links innate immunity with mitochondrial metabolism in driving pancreatic cancer  \nReceived: 28 May 2025  \n\n| Accepted: 27 January 2026 |\n| --- |\n| |\n| Check for updates |\n\nYu C. J. Chey 1,13, Bassam Kashgari2,3,13, Louise McLeod2,3, Georgette A. Radford1, Linden J. Gearing 2,3, Ruby E. Dawson1, Malvika Kharbanda 1, Joanne Lundy2,3,4,5, Daniel Croagh 4,  \nCharlotte Girard-Guyonvarc’h 6,7, Cem Gabay 6,7, Brooke A. Pereira 8,9, David Herrmann 8,9, Paul Timpson 8,9, John W. Finnie10, Mohamed I. Saad 1, Dharmesh D. Bhuva 1,11, Bernardo S. Franklin 12, Florian I. Schmidt 12 & Brendan J. Jenkins 1,2,3   \nPancreatic ductal adenocarcinoma (PDAC) is driven by genetic alterations in the pancreatic epithelium (e.g., KRAS) coupled with dysregulated innate immunity that triggers tumor-promoting chronic inﬂammation. However, the identity of innate immune molecular regulators as therapeutic targets in PDACis ill-deﬁned. Here, we show in PDAC patients that elevated tumoral expression ofthe inﬂammasome adaptor protein ASC and its downstream effector Caspase-1 is primarily colocalized to the pancreatic ductal epithelium and prognostic for poor survival. In the mutant Kras-driven KPC PDAC mouse model, global and conditional (pancreatic epithelial) ablation ofASC, or nanobody-mediated targeting of extracellular ASC, suppresses pancreatic tumorigenesis. Whole transcriptome proﬁling and multiplex immunoﬂuorescence reveal that the tumor-promoting activities of epithelial-derived ASC align with molecular pathways for mitochondrial respiration, metabolism (glycolysis), and immune responses. Our discovery that ASC-containing inﬂammasomes promote PDAC by acting as a molecular bridge between innate immunity, mitochondrial dysfunction and metabolic reprogramming provides the rationale to therapeutically target ASC in cancers.  \nPancreatic cancer is predicted to be the second most lethal cancer in Western countries by 2030 and is associated with a low overall 5-year survival rate of10–12%1–3. Poor survival outcomes for pancreatic cancer are linked to late detection in 80% of patients diagnosed with inoperable locally advanced or metastatic late-stage disease, and the limited effectiveness ofcurrent standard-of-care chemotherapy regimens, and more recently immunotherapy3,4. The overwhelming majority  \n(~90%) of cases present as pancreatic ductal adenocarcinoma (PDAC), driven by genetic alterations in the pancreas epithelium (e.g., KRAS, 90%; TP53, \u003C70%) coupled with a highly heterogenic tumor microenvironment (TME) that invariably exists in an immunosuppressivestate3–5.  \nChronic inﬂammation driven by uncontrolled activation of the innate arm of the immune system is associated with at least 30% of all  \nA full list of afﬁliations appears at the end of the paper. e-mail: [brendan.jenkins@adelaide.edu.au](brendan.jenkins@adelaide.edu.au)  \ncancers, including PDAC, and is one of the hallmarks of cancer6–9. In PDAC, the chronically inﬂamedTMEis enriched in innate immune cells (e.g., tumor-associated macrophages, myeloid-derived suppressor cells (MDSCs), neutrophils, dendritic cells), which synergize with the transformed pancreatic epithelium and other stromal cellular components (i.e. cancer-associated ﬁbroblasts, endothelial cells) to release a myriad of inﬂammatory cytokines (e.g. IL-1β, IL-6, IL-10, TNFα), chemokines (e.g., CCL2, CXCL1, CXCL12), growth (e.g., TGFβ), and angiogenic (e.g., VEGF) factors that propagate a pro-tumorigenic TME4,5,10,11. Despite the burgeoning evidence for innate immunity promoting the pathogenesis of PDAC, immune-based therapies for PDAC patients have been restricted to inhibitors targeting immune checkpoints of adaptive immunity, namely PD-1, PD-L1 and CTLA-4, with minimal clinical beneﬁt4,5.  \nInnate immune-driven inﬂammatory responses to microbial infection and sterile injury depend on","cbCaihQSWDF6sPLk","https://ap.wps.com/l/cbCaihQSWDF6sPLk","pdf",7456450,21,"English","# Background: PDAC, innate immunity, and inflammasomes\n## Patient findings: ASC/Caspase-1 localization and prognosis\n## Mouse models and functional targeting of ASC\n## Mechanistic links: epithelial ASC, mitochondria, metabolism, immune pathways","[{\"question\":\"What relationship between ASC and prognosis is reported in pancreatic cancer patients?\",\"answer\":\"Tumoral ASC expression, along with Caspase-1, is primarily colocalized to the pancreatic ductal epithelium and is prognostic for poor survival.\"},{\"question\":\"How does targeting ASC affect pancreatic tumor development in the KPC mouse model?\",\"answer\":\"Global or conditional ablation of ASC, or nanobody-mediated targeting of extracellular ASC, suppresses pancreatic tumorigenesis.\"},{\"question\":\"What mechanisms link ASC-containing inflammasomes to PDAC according to the article?\",\"answer\":\"Epithelial-derived ASC aligns with pathways for mitochondrial respiration, metabolic reprogramming (including glycolysis), and immune responses, forming a molecular bridge between innate immunity, mitochondrial dysfunction, and metabolic changes.\"}]","Cancer cell-intrinsic inflammasome protein ASC links innate immunity with mitochondrial metabolism in driving pancreatic cancer | PDF",1790055909,53,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f1396188c9836ff31d31ffd63a42de52.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7f010cdec9e7fd7891b7e18a121570c4.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e12f604f20ad4b4f3f6be8d93078a5b9.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9726c7d5748bcf6756dd092f80162bcd.webp",980,1301]